Actavis Said To Be in Talks With Allergan on $60B Deal

The transcript discusses a potential acquisition involving a drug company known for Botox and implants, with rival drugmaker Activist in talks to buy it for $60 billion. Bill Ackman, a major shareholder, plays a significant role in the proceedings. The discussion includes stock performance of Activist and Allergan, and the involvement of hedge funds like Third Point and Blue Ridge. Key players and their strategies are highlighted, providing insights into the financial maneuvers surrounding the acquisition.

How has the stock price of Allergan been described in the context of the discussion?

What challenges has Bill Ackman faced with Allergan's senior management?